Insulet consensus stays moderate, shares trade below analyst targets

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 15:12.

Insulet (US45784P1012) sits on a Moderate Buy rating profile among Wall Street houses. The diabetes technology group is listed on NASDAQ, and current consensus data underline a marked gap between the share price and average analyst targets, according to MarketBeat.

What analysts say on Insulet

MarketBeat aggregates 28 analyst opinions on Insulet, with a consensus rating of "Moderate Buy" and a score of 2.71 on a 0-4 scale, signaling a cautiously positive stance from the research community. MarketBeat consensus overview on Insulet The average 12-month price target stands at 238.67 US dollars, with a high target of 375 dollars and a low of 165 dollars, illustrating a wide expectation range for the stock. MarketBeat analyst price-target breakdown

The potential upside versus the current share price is calculated at 50.8 percent based on that average target, highlighting that most covering analysts still see room above prevailing market levels. MarketBeat price-target and upside data The breadth of coverage with nearly 30 firms also indicates that Insulet remains firmly on the institutional radar within the US medtech universe.

How Insulet shares are valued today

Insulet shares last closed at 158.25 US dollars on NASDAQ on 2026-06-26 at 16:00 Eastern Time, with extended-hours trading printing 158.50 dollars at 04:38 Eastern on the following session per MarketBeat price data. MarketBeat quote and extended-hours data Over the past 50 days, the trading range ran between 138.97 and 203.73 dollars, reflecting solid volatility in the medtech segment. MarketBeat 50-day trading range chart

The daily range on the last regular session spanned from 154.45 to 160.92 dollars, positioning the latest close in the upper half of the intraday band. MarketBeat intraday high-low data With the stock trading significantly below the consensus target, investors can clearly see how the current market price compares with the aggregated analyst view at a glance.

The product behind the stock

Insulet generates its revenues primarily with the Omnipod insulin management system, a tubeless insulin pump designed for people with diabetes who require insulin therapy. Insulet product overview for Omnipod The Omnipod platform combines wearable pods with a handheld controller, enabling continuous insulin delivery without traditional tubing-based pumps. Insulet business description and product focus

Where the Insulet shares trade

The Insulet shares (US45784P1012) last traded on NASDAQ at 158.25 US dollars as of 2026-06-26, 16:00 Eastern Time, with an extended-hours indication of 158.50 dollars at 04:38 Eastern reported by MarketBeat.

This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data and assessments are based on sources cited in the article and may change over time.